Literature DB >> 21620777

Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth.

David J Mulholland1, Linh M Tran, Yunfeng Li, Houjian Cai, Ashkan Morim, Shunyou Wang, Seema Plaisier, Isla P Garraway, Jiaoti Huang, Thomas G Graeber, Hong Wu.   

Abstract

Alteration of the PTEN/PI3K pathway is associated with late-stage and castrate-resistant prostate cancer (CRPC). However, how PTEN loss is involved in CRPC development is not clear. Here, we show that castration-resistant growth is an intrinsic property of Pten null prostate cancer (CaP) cells, independent of cancer development stage. PTEN loss suppresses androgen-responsive gene expressions by modulating androgen receptor (AR) transcription factor activity. Conditional deletion of Ar in the epithelium promotes the proliferation of Pten null cancer cells, at least in part, by downregulating the androgen-responsive gene Fkbp5 and preventing PHLPP-mediated AKT inhibition. Our findings identify PI3K and AR pathway crosstalk as a mechanism of CRPC development, with potentially important implications for CaP etiology and therapy.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21620777      PMCID: PMC3157296          DOI: 10.1016/j.ccr.2011.05.006

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  64 in total

1.  Trimming of mammalian transcriptional networks using network component analysis.

Authors:  Linh M Tran; Daniel R Hyduke; James C Liao
Journal:  BMC Bioinformatics       Date:  2010-10-13       Impact factor: 3.169

2.  Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model.

Authors:  David J Mulholland; Li Xin; Ashkan Morim; Devon Lawson; Owen Witte; Hong Wu
Journal:  Cancer Res       Date:  2009-11-03       Impact factor: 12.701

3.  Development of a second-generation antiandrogen for treatment of advanced prostate cancer.

Authors:  Chris Tran; Samedy Ouk; Nicola J Clegg; Yu Chen; Philip A Watson; Vivek Arora; John Wongvipat; Peter M Smith-Jones; Dongwon Yoo; Andrew Kwon; Teresa Wasielewska; Derek Welsbie; Charlie Degui Chen; Celestia S Higano; Tomasz M Beer; David T Hung; Howard I Scher; Michael E Jung; Charles L Sawyers
Journal:  Science       Date:  2009-04-09       Impact factor: 47.728

4.  FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt.

Authors:  Huadong Pei; Liang Li; Brooke L Fridley; Gregory D Jenkins; Krishna R Kalari; Wilma Lingle; Gloria Petersen; Zhenkun Lou; Liewei Wang
Journal:  Cancer Cell       Date:  2009-09-08       Impact factor: 31.743

5.  Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer.

Authors:  Weisheng Zhang; Joe Zhu; Clay L Efferson; Chris Ware; Jennifer Tammam; Minilik Angagaw; Jason Laskey; Kimberly A Bettano; Shailaja Kasibhatla; John F Reilly; Cyrille Sur; Pradip K Majumder
Journal:  Cancer Res       Date:  2009-09-08       Impact factor: 12.701

Review 6.  Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.

Authors:  Gerhardt Attard; Alison H M Reid; David Olmos; Johann S de Bono
Journal:  Cancer Res       Date:  2009-06-09       Impact factor: 12.701

7.  Pathological effects of prostate cancer correlate with neuroendocrine differentiation and PTEN expression after bicalutamide monotherapy.

Authors:  Won Sik Ham; Nam Hoon Cho; Won Tae Kim; Hee Jeong Ju; Jin Sun Lee; Young Deuk Choi
Journal:  J Urol       Date:  2009-08-14       Impact factor: 7.450

8.  Androgen sensitivity of prostate epithelium is enhanced by postnatal androgen receptor inactivation.

Authors:  Ulla Simanainen; Keely McNamara; Yan Ru Gao; David J Handelsman
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-04-14       Impact factor: 4.310

Review 9.  PTEN, stem cells, and cancer stem cells.

Authors:  Reginald Hill; Hong Wu
Journal:  J Biol Chem       Date:  2008-12-30       Impact factor: 5.157

Review 10.  Is EGR1 a potential target for prostate cancer therapy?

Authors:  Delphine Gitenay; Véronique T Baron
Journal:  Future Oncol       Date:  2009-09       Impact factor: 3.404

View more
  267 in total

1.  Pleckstrin homology domain leucine-rich repeat protein phosphatase (PHLPP): a new player in cell signaling.

Authors:  Noel A Warfel; Alexandra C Newton
Journal:  J Biol Chem       Date:  2011-12-05       Impact factor: 5.157

Review 2.  Prostate cancer in 2011: redefining the therapeutic landscape for CRPC.

Authors:  Carmel Pezaro; Gerhardt Attard
Journal:  Nat Rev Urol       Date:  2012-01-17       Impact factor: 14.432

3.  Suppression of survival signalling pathways by the phosphatase PHLPP.

Authors:  Audrey K O'Neill; Matthew J Niederst; Alexandra C Newton
Journal:  FEBS J       Date:  2012-03-16       Impact factor: 5.542

4.  VEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancer.

Authors:  Hira Lal Goel; Cheng Chang; Bryan Pursell; Irwin Leav; Stephen Lyle; Hualin Simon Xi; Chung-Cheng Hsieh; Helty Adisetiyo; Pradip Roy-Burman; Ilsa M Coleman; Peter S Nelson; Robert L Vessella; Roger J Davis; Stephen R Plymate; Arthur M Mercurio
Journal:  Cancer Discov       Date:  2012-07-09       Impact factor: 39.397

5.  Targeted androgen pathway suppression in localized prostate cancer: a pilot study.

Authors:  Elahe A Mostaghel; Peter S Nelson; Paul Lange; Daniel W Lin; Mary Ellen Taplin; Steven Balk; William Ellis; Philip Kantoff; Brett Marck; Daniel Tamae; Alvin M Matsumoto; Lawrence D True; Robert Vessella; Trevor Penning; Rachel Hunter Merrill; Roman Gulati; Bruce Montgomery
Journal:  J Clin Oncol       Date:  2013-12-09       Impact factor: 44.544

Review 6.  Molecular pathology of prostate cancer revealed by next-generation sequencing: opportunities for genome-based personalized therapy.

Authors:  Jiaoti Huang; Jason K Wang; Yin Sun
Journal:  Curr Opin Urol       Date:  2013-05       Impact factor: 2.309

7.  Crosstalk between nuclear MET and SOX9/β-catenin correlates with castration-resistant prostate cancer.

Authors:  Yingqiu Xie; Wenfu Lu; Shenji Liu; Qing Yang; Brett S Carver; Estelle Li; Yuzhuo Wang; Ladan Fazli; Martin Gleave; Zhenbang Chen
Journal:  Mol Endocrinol       Date:  2014-08-06

Review 8.  Novel therapies for the treatment of advanced prostate cancer.

Authors:  J M Clarke; A J Armstrong
Journal:  Curr Treat Options Oncol       Date:  2013-03

9.  MEF2 is a converging hub for histone deacetylase 4 and phosphatidylinositol 3-kinase/Akt-induced transformation.

Authors:  Eros Di Giorgio; Andrea Clocchiatti; Sara Piccinin; Andrea Sgorbissa; Giulia Viviani; Paolo Peruzzo; Salvatore Romeo; Sabrina Rossi; Angelo Paolo Dei Tos; Roberta Maestro; Claudio Brancolini
Journal:  Mol Cell Biol       Date:  2013-09-16       Impact factor: 4.272

10.  Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention.

Authors:  Shidong Jia; Xueliang Gao; Sang Hyun Lee; Sauveur-Michel Maira; Xiaoqiu Wu; Edward C Stack; Sabina Signoretti; Massimo Loda; Jean J Zhao; Thomas M Roberts
Journal:  Cancer Discov       Date:  2012-12-20       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.